Skip to search formSkip to main contentSkip to account menu

Gadobenate

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
ObjectiveThe purpose of this study was to determine whether gadolinium (Gd) is deposited in brain and bone tissues in patients… 
Highly Cited
2010
Highly Cited
2010
OBJECTIVE The purpose of this study was to retrospectively assess the frequency, manifestations, and severity of acute adverse… 
Highly Cited
2008
Highly Cited
2008
OBJECTIVE The objective of our study was to intraindividually compare 0.1 mmol/kg doses of gadobenate dimeglumine and… 
Review
2005
Review
2005
Institutional review board approval and patient written informed consent were obtained. On two separate occasions, 24 hours apart… 
Highly Cited
2003
Highly Cited
2003
Schneider G, Maas R, Kool LS, et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast… 
Highly Cited
2000
Highly Cited
2000
OBJECTIVE We evaluated the extent to which hepatic lesion characterization and detection is improved by using gadobenate… 
Highly Cited
1999
Highly Cited
1999
RATIONALE AND OBJECTIVES To determine the safety and pharmacokinetics of gadobenate dimeglumine in a group of subjects with… 
Highly Cited
1997
Highly Cited
1997
RATIONALE AND OBJECTIVES The authors assess the effect of weak protein binding on the efficacy of gadolinium chelates as contrast… 
Highly Cited
1992
Highly Cited
1992
Gadobenate dimeglumine (formerly known as Gd-BOPTA) is a recently developed paramagnetic contrast agent that undergoes biliary as…